Streetbeat News

Earnings

AXDX

Accelerate Diagnostics (NASDAQ:AXDX) reported Q1 losses of $(1.70) per share, missing the analyst consensus estimate of $(1.40) by 21.43%. This is a 32% increase over losses from the same period last year. The company also reported quarterly sales of $2.81 million, missing the analyst consensus estimate of $3.35 million by 16.06%. This is a 4.94% decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:20 pm

VOR

Vor Bio has reported its Q2 2023 cash and cash equivalents to be $186.9M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:19 pm

SBIG

SpringBig Holdings (NASDAQ:SBIG) reported Q2 losses of $(0.06) per share, missing the analyst consensus estimate of $(0.04) by 50%. The company also reported quarterly sales of $7.21 million, missing the analyst consensus estimate of $7.30 million by 1.18%. However, both losses and sales showed an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:17 pm

YCBD

cbdMD reported Q3 losses of $(1.16) per share, a 95.31% increase from $(24.75) per share YoY. The company's sales were $6.12M, a 28.79% decrease from $8.59M YoY.

Portfolio Pulse from totan@benzinga.com

August 10, 2023 | 9:17 pm

CANO

Cano Health, Inc. (NYSE:CANO) reported worse-than-expected Q2 results, with losses of 51 cents per share, missing the analyst consensus estimate of losses of 12 cents. The company also reported quarterly sales of $766.70 million, missing the analyst consensus estimate of $828.43 million. Despite missing top and bottom line estimates, total membership increased. Cano Health is considering selling the company and plans to exit operations in California, New Mexico, and Illinois by fall 2023, and Puerto Rico by January 1, 2024. The company is also withdrawing its fiscal year 2023 guidance.

Portfolio Pulse from Ryan Gustafson

August 10, 2023 | 9:16 pm

ACHR

Archer, a US-listed company, reported its Q2 2023 total operating expenses as $77.4M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:16 pm

SFE

Safeguard Scientifics (NYSE:SFE) reported Q2 losses of $(0.18) per share, a 700% decrease from earnings of $0.03 per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:16 pm

TYRA

Tyra Biosciences reported Q2 losses of $(0.31) per share, beating the analyst consensus estimate of $(0.34) by 8.82 percent. This represents a 13.89 percent improvement over losses of $(0.36) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:16 pm

TARS

Tarsus Pharmaceuticals reported Q2 losses of $(1.17) per share, a 387.5% decrease from the same period last year when losses were $(0.24) per share.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:15 pm

POAI

Predictive Oncology (NASDAQ:POAI) reported Q2 losses of $(0.98) per share, a 67.33% increase from $(3.00) per share YoY. The company also reported a 31.90% increase in sales to $490.11K from $371.59K YoY.

Portfolio Pulse from bharat@benzinga.com

August 10, 2023 | 9:15 pm